Company Overview and News
New Zealand shares gained as the dollar sank following the official cash rate update, with Pushpay Holdings recovering from recent selling and SkyCity Entertainment Group continuing to gain.
KTHDY FBU FCREY NZR FRCEF FTRRF KMD SKC PPSHY FBU VTHPF GTK KMD
New Zealand shares gained, led higher by Freightways and Sky Network Television as the market remains quiet ahead of earnings season.
CEN ZNRGF KMD COENF SKT ZNZ GNE SYKWF SKC CEN SKKTY FGHRY KMD GEL KTHDY EBOSY FLT ZEL EBO COENY KWIPF EBOSF EVO GNE GTK EBO
Gentrack Group said it raised about $25.8 million in a stock offer to retail investors, in the second part of a two-stage share sale aimed at raising funds to repay debt used for a recent flurry of acquisitions.
Gentrack Group said it raised about $52.4 million in a discounted stock offer to institutional investors as part of a two-stage share sale aimed at raising funds to repay debt used for a recent flurry of acquisitions.
New Zealand shares were mixed in light trading, with Sky Network Television and Stride Property leading gains while A2 Milk Co and Westpac Banking Corp fell.
AIA WBC WEBNF WBK ACKDF AUKNY SKT SYKWF AIA WBC VTHPF SKKTY GTK SML
New Zealand shares rose, led by Auckland International Airport, Spark and Fisher & Paykel Healthcare and as buyers returned to A2 Milk. Gentrack Group fell as earnings growth disappointed some bullish investors.
AIA WBC AIA WBC GTK WEBNF GXH WBK ACKDF AUKNY PRCXF
Gentrack Group lifted first-half earnings 80 per cent as the utilities software developer benefited from new projects and acquisitions made last year and said it had a strong pipeline of opportunities.
2018-08-13 - Asif
Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...
2018-08-13 - Asif
Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...
2018-08-13 - Asif
Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...